Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
20,209,985
-
Shares change
-
+321,088
-
Total reported value, excl. options
-
$210,368,267
-
Value change
-
+$3,880,985
-
Put/Call ratio
-
59%
-
Number of buys
-
43
-
Number of sells
-
-31
-
Price
-
$10.41
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2016
105 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2016.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,209,985 shares
of 236,234,693 outstanding shares and own 8.56% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3,499,357 shares), Nantahala Capital Management, LLC (2,232,408 shares), BlackRock Fund Advisors (1,703,987 shares), VANGUARD GROUP INC (1,196,235 shares), FIRST MANHATTAN CO (1,038,500 shares), FMR LLC (931,855 shares), venBio Select Advisor LLC (831,515 shares), MORGAN STANLEY (815,073 shares), BlackRock Institutional Trust Company, N.A. (796,132 shares), and ACUTA CAPITAL PARTNERS, LLC (698,825 shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.